Hutchison China MediTech (Chi-Med) has initiated its Phase II study by administering the first dose of sulfatinib to treat second-line biliary tract cancer (BTC) patients in China.
Sulfatinib is an orally administered, angio-immunokinase inhibitor developed to selectively target vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and colony-stimulating factor-1 receptor (CSF-1R), the three key tyrosine kinase receptors considered responsible for tumour angiogenesis and immune evasion.
The Phase II study is being conducted as a multi-centre, single-arm, open-label trial intended to test the safety and efficacy of sulfatinib as a monotherapy to treat advanced or metastatic BTC patients who failed one prior systemic therapy.
BTC, also known as cholangiocarcinoma, is a rare, fatal disease condition arising from the biliary tract epithelia, including intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. It is the second most frequently occurring type of liver cancer in the world.
The study’s primary endpoint is progression free survival (PFS) after administering sulfatinib for 16 weeks and its secondary endpoints are objective response rate (ORR), disease control rate (DCR), duration of response, PFS, overall survival (OS) and safety.
See Also:
In addition to the BTC trial, six sulfatinib clinical trials are underway in China and the US, including two Phase III studies known as SANET-p and SANET-ep and a Phase II study in thyroid cancer patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData